Answers are grounded in this paper and cite their sources.
The role of cyclooxygenase-2 (COX-2), a well-known pharmacological target for attenuating inflammation, in regulating obesity and its comorbidities remains unclear. We sought to determine the role of COX-2 in modulating metabolic inflammation and systemic metabolic homeostasis in obesity. Male WT and COX-2 KO mice were fed a chow diet or a high fat diet (HF, 45% fat) for 13 weeks. While the body weight gain did not alter, the visceral adipose tissue mass was significantly higher in KO-HF mice than in WT-HF mice. Plasma triglycerides and total cholesterol levels were higher in KO-HF mice than in WT-HF mice. Total body fat mass was higher with a concomitant reduction in lean mass in KO-HF mice than in WT-HF mice. Paradoxically, hepatic steatosis was reduced in KO-HF mice. While liver triglycerides were reduced, the liver cholesterol was increased in KO-HF mice. Bile acids and markers of cholesterol biosynthesis were unaltered between WT-HF and KO-HF groups. The mRNA and/or protein levels of autophagy markers were significantly decreased in KO-HF mice compared to WT-HF mice, indicating that a reduction in autophagy may increase cholesterol levels in these mice. The liver inflammatory markers were significantly increased only in WT mice fed a HF diet but not in KO-HF fed mice compared to their respective controls. Visceral adipose tissue showed a reduction in inflammatory markers in spite of an increase in adiposity. These data suggest that despite being effective in attenuating the inflammatory processes, inhibition of COX-2 exerts undesirable consequences on metabolic homeostasis.
No takes yet. Share an insight, caveat, or question.
Balakrishnan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: